Escobedo L, Avilés R, Zavala I, Rendón A, Orzechowski A, Torre BF, Moreno F, Morán O, Tamez R, Ramírez E, Saldate C, Barbosa JA, Marcano G, Kancheff K, Contreras G, Philippe A

Language: Spanish
References: 16
Page: 64-72
PDF size: 107.57 Kb.

ABSTRACT

Multicenter case-series to evaluate safety and clinical and bacteriologic efficacy of oral gatifloxacin, 400 mg once a day during 7-10 days, in the treatment of 91 patients with an acute exacerbation of chronic bronchitis in Mexico. Clinical response in the end of treatment visit was: 69 patients cured (76%), 14 patients improved (15%) and one patient failed (1%); there were 7 patients (8%) unable to be assessed in a subsequent visit to evaluate relapse. Final response, was: cure in 75 patients (82%), relapse in 5 patients (6%) and 11 patients were unable to be assessed (12%). In all 20 (22%) patients in whom a microorganism considered pathogenic was isolated (35%), bacteriologic eradication was achieved. Most commonly reported adverse events were nausea, abdominal pain, diarrhea and flatulence. Gatifloxacin proved to be safe and effective when administered during 7-10 days to Mexican patients with acute exacerbation of chronic bronchitis. Yet, this study does not assess the benefit of gatifloxacin relative to other antibiotics or to with holding any antimicrobial therapy.

REFERENCES

1. Barter CE, Campell AH. Relationship of constitutional factors and cigarette smoking to disease in. 1. Second forced expiratory volume. Am Rev Respir Dis 1976;113:305-14.

2. American Thoracic Society Statement. Standards for the diagnosis and care of patient with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:78-121.

3. Huib AM Kerstjens. Stable chronic obstructive pulmonary disease. British Medical Journal 1999;(319):495-500.

4. Cicero R. Ramirez E. Enfermedad pulmonar obstructiva crónica en dos hospitales de la ciudad de México. Rev Inst Nac de Enf Resp 1995;8:16-25.

5. Sansores RH, Pérez-Padilla R. Enfermedad pulmonar obstructiva crónica. Un problema mundial. Un enfoque en México. Editorial Piensa. México 1997.

6. Ronald F, Grossman MD. Part 1: Beating Bronchitis. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997;112:310-315.

7. Ronald F, Grossman MD. The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPC. Chest 1998;(113): 249-57.

8. Ramirez Alicia. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial results. J Respiratory Dis 1999;20 (suppl):S30-S39.

9. Zhao X, Su C, Domagala J. DNA topoisomerase targets of the fluoroquinolones; a strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA 1997;94:1391-96.

10. DeAbate CA, Robert A. Mclvor. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis. J Respiratory Dis 1999;20(suppl):S23-S29.

11. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.

12. Pérez-Padilla R, Regalado PJ. La inhalación doméstica del humo de leña y otros materiales biológicos. Un riesgo para el desarrollo de enfermedades respiratorias. Gac Med Mex 1999;(135)1:19-29.

13. Mason EO, Lamberth L, Lichenstein R, et al. Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in vitro susceptibility to selected oral antibiotics. J Antimicrob Chemother 1995;36:1043-1048.

14. Piddock LJ, Johnson M, Ricci V, et al. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother 1998;42:2956-2960.

15. Chen DK, McGeer A, de Azavedo JC, et al. Decrease susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-9.

16. National Committee for Clinical Laboratory Standards. Document M100s9; 18(1-2)2nd Wayne Penn USA 1999.